Ongoing Lessons from the Comprehensive ESRD Care Program.
作者信息
Kinlaw Alan C, Kshirsagar Abhijit V
机构信息
Division of Pharmaceutical Outcomes and Policy, University of North Carolina School of Pharmacy, Chapel Hill, North Carolina.
Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
出版信息
Kidney360. 2022 May 5;3(6):988-990. doi: 10.34067/KID.0008142021. eCollection 2022 Jun 30.
Abstract
摘要
相似文献
1
Ongoing Lessons from the Comprehensive ESRD Care Program.来自终末期肾病综合护理项目的持续经验教训。
Kidney360. 2022 May 5;3(6):988-990. doi: 10.34067/KID.0008142021. eCollection 2022 Jun 30.
3
Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, and End-Stage Renal Disease Quality Incentive Program. Final rule.医疗保险计划；终末期肾病前瞻性支付系统、向急性肾损伤患者提供的肾透析服务支付以及终末期肾病质量激励计划。最终规则。
Fed Regist. 2017 Nov 1;82(210):50738-97.
4
Value-Based Care and Kidney Disease: Emergence and Future Opportunities.基于价值的医疗保健与肾脏病：出现和未来机遇。
Adv Chronic Kidney Dis. 2022 Jan;29(1):30-39. doi: 10.1053/j.ackd.2021.10.001.
5
Renal Dialysis and its Financing.肾透析及其融资
Hosp Top. 2016 Apr-Jun;94(2):33-8. doi: 10.1080/00185868.2016.1175203.
6
The Role of Social Risk Factors in Dialysis Quality and Patient Outcomes Under a Medicare Quality Incentive Program.社会风险因素在医疗保险质量激励计划下对透析质量和患者预后的作用。
Med Care. 2022 Oct 1;60(10):735-742. doi: 10.1097/MLR.0000000000001750. Epub 2022 Jul 26.
7
Mortality Risk of Patients Treated in Dialysis Facilities with Payment Reductions under ESRD Quality Incentive Program.接受 ESRD 质量激励计划下支付削减的透析设施治疗的患者的死亡率风险。
Clin J Am Soc Nephrol. 2023 Mar 1;18(3):356-362. doi: 10.2215/CJN.0000000000000079. Epub 2023 Feb 8.
8
The ESRD Quality Incentive Program-Can We Bridge the Chasm?终末期肾病质量激励计划——我们能弥合差距吗？
J Am Soc Nephrol. 2017 Jun;28(6):1697-1706. doi: 10.1681/ASN.2016101079. Epub 2017 Mar 15.
9
Value-Based Kidney Care: A Recipe for Success.基于价值的肾脏护理：成功秘诀
Clin J Am Soc Nephrol. 2021 Oct;16(10):1467-1469. doi: 10.2215/CJN.11250821.
10
Managing oral phosphate binder medication expenditures within the Medicare bundled end-stage renal disease prospective payment system: economic implications for large U.S. dialysis organizations.在 Medicare 捆绑式终末期肾脏疾病前瞻性支付系统中管理口服磷酸盐结合剂药物支出：对美国大型透析组织的经济影响。
J Manag Care Spec Pharm. 2015 Jun;21(6):507-14. doi: 10.18553/jmcp.2015.21.6.507.
本文引用的文献
1
Association of the Comprehensive ESRD Care Model with Treatment Adherence.综合终末期肾病护理模式与治疗依从性的关联。
Kidney360. 2021 Dec 21;3(6):1039-1046. doi: 10.34067/KID.0006132021. eCollection 2022 Jun 30.
2
The table 2 fallacy: presenting and interpreting confounder and modifier coefficients.表 2 谬误：呈现和解释混杂因素和修饰因素系数。
Am J Epidemiol. 2013 Feb 15;177(4):292-8. doi: 10.1093/aje/kws412. Epub 2013 Jan 30.
3
Development of an end-stage renal disease managed care demonstration.终末期肾病管理式医疗示范项目的开展。
Adv Ren Replace Ther. 1997 Oct;4(4):332-9. doi: 10.1016/s1073-4449(97)70022-0.
4
The statistical basis of meta-analysis.荟萃分析的统计学基础。
Stat Methods Med Res. 1993;2(2):121-45. doi: 10.1177/096228029300200202.
Zotero 插件